A Randomized, Double-Blind, Double-Dummy, Active-Comparator, Multicenter Study to Evaluate the Efficacy and Safety of Rituximab Versus MMF in Patients With Pemphigus Vulgaris
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 09 Apr 2018
At a glance
- Drugs Rituximab (Primary) ; Mycophenolate mofetil
- Indications Pemphigus vulgaris
- Focus Therapeutic Use
- Acronyms PEMPHIX
- Sponsors Roche
- 05 Apr 2018 Status changed from recruiting to active, no longer recruiting.
- 27 Feb 2018 Status changed from active, no longer recruiting to recruiting.
- 27 Feb 2018 Planned End Date changed from 7 Sep 2019 to 7 Nov 2019.